Real-world study on the efficacy and safety of vedolizumab in the maintenance treatment of ulcerative colitis
10.3760/cma.j.cn101480-20231102-00056
- VernacularTitle:维得利珠单克隆抗体维持治疗溃疡性结肠炎疗效及安全性的真实世界研究
- Author:
Qiao YU
1
;
Jiakai LUO
;
Yuting WANG
;
Xiaoying WANG
;
Dingting XU
;
Hanyun ZHANG
;
Minfang LYU
;
Yan MA
;
Shuyan LI
;
Xiaoxu HUANG
;
Miaoyan CHEN
;
Xiujun LIAO
;
Dong XU
;
Yan CHEN
Author Information
1. 浙江大学医学院附属第二医院消化内科，杭州 310009
- Publication Type:Journal Article
- Keywords:
Ulcerative colitis;
Vedolizumab;
Real-world;
Maintenance treatment;
Efficacy;
Safety
- From:
Chinese Journal of Inflammatory Bowel Diseases
2024;08(2):144-148
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy and safety of vedolizumab (VDZ) monoclonal antibody in maintenance therapy for ulcerative colitis (UC) .Methods:A retrospective case control study was conducted, including 84 patients with active UC undergoing VDZ therapy for an average of (22±8) weeks in the Department of Gastroenterology, the Second Affiliated Hospital of Zhejiang University School of Medicine from December 2020 to September 2023. These patients achieved a response or remission by (22±8) weeks and continued follow-up until (54±8) weeks. They were divided into effective and ineffective groups based on whether they achieved clinical remission by (54±8) weeks after using VDZ; those who required optimized treatment with shortened injection intervals were included in the ineffective group. Baseline clinical data, medication history and endoscopic imaging data were recorded. The clinically modified Mayo score, Mayo endoscopic score, and other assessments were used to evaluate UC disease activity. Adverse reactions related to treatment were also recorded to assess the efficacy of VDZ treatment up to (54±8) weeks was assessed and key factors affecting clinical remission of the disease were analyzed.Results:Among the 84 UC patients with followed up to (54±8) weeks, 47 cases (55.95%) achieved clinical remission and were classified as the effective group, while 37 cases (44.05%) did not achieve clinical remission and were classified as the ineffective group. The endoscopic remission rate in the effective group was 68.09% (32/47), and the mucosal healing rate was 36.17% (17/47). Joint pain occurred in 2.38% of patients, hepatic dysfunction in 3.57%, and one patient died from leukemia following a COVID-19 infection during the maintenance therapy period.Conclusion:VDZ has a certain efficacy in the continuous treatment of UC patients and in maintaining clinical and endoscopic remission, with generally high overall safety and a low incidence of adverse reactions.
